1 Anti-epileptic Drugs for Pediatrics Market Overview 1.1 Product Overview and Scope of Anti-epileptic Drugs for Pediatrics 1.2 Anti-epileptic Drugs for Pediatrics Segment by Type 1.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 1st Generation 1.2.3 2nd Generation 1.2.4 3rd Generation 1.3 Anti-epileptic Drugs for Pediatrics Segment by Application 1.3.1 Global Anti-epileptic Drugs for Pediatrics Sales Comparison by Application: (2021-2027) 1.3.2 Hospitals 1.3.3 Retail Pharmacies 1.3.4 Online Pharmacies 1.4 Global Anti-epileptic Drugs for Pediatrics Market Size Estimates and Forecasts 1.4.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2016-2027 1.4.2 Global Anti-epileptic Drugs for Pediatrics Sales 2016-2027 1.4.3 Anti-epileptic Drugs for Pediatrics Market Size by Region: 2016 Versus 2021 Versus 2027 2 Anti-epileptic Drugs for Pediatrics Market Competition by Manufacturers 2.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2016-2021) 2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Anti-epileptic Drugs for Pediatrics Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Anti-epileptic Drugs for Pediatrics Manufacturing Sites, Area Served, Product Type 2.5 Anti-epileptic Drugs for Pediatrics Market Competitive Situation and Trends 2.5.1 Anti-epileptic Drugs for Pediatrics Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Anti-epileptic Drugs for Pediatrics Players Market Share by Revenue 2.5.3 Global Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario by Region 3.1 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.3.1 North America Anti-epileptic Drugs for Pediatrics Sales by Country 3.3.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.4.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Country 3.4.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Region 3.5.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region 3.5.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.6.1 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country 3.6.2 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.7.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country 3.7.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Anti-epileptic Drugs for Pediatrics Historic Market Analysis by Type 4.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2016-2021) 4.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2016-2021) 4.3 Global Anti-epileptic Drugs for Pediatrics Price by Type (2016-2021) 5 Global Anti-epileptic Drugs for Pediatrics Historic Market Analysis by Application 5.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2016-2021) 5.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2016-2021) 5.3 Global Anti-epileptic Drugs for Pediatrics Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Mylan N.V 6.1.1 Mylan N.V Corporation Information 6.1.2 Mylan N.V Description and Business Overview 6.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Product Portfolio 6.1.5 Mylan N.V Recent Developments/Updates 6.2 Cephalon, Inc 6.2.1 Cephalon, Inc Corporation Information 6.2.2 Cephalon, Inc Description and Business Overview 6.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.2.5 Cephalon, Inc Recent Developments/Updates 6.3 GlaxoSmithKline plc 6.3.1 GlaxoSmithKline plc Corporation Information 6.3.2 GlaxoSmithKline plc Description and Business Overview 6.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.3.5 GlaxoSmithKline plc Recent Developments/Updates 6.4 Janssen Pharmaceuticals 6.4.1 Janssen Pharmaceuticals Corporation Information 6.4.2 Janssen Pharmaceuticals Description and Business Overview 6.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio 6.4.5 Janssen Pharmaceuticals Recent Developments/Updates 6.5 Novartis AG 6.5.1 Novartis AG Corporation Information 6.5.2 Novartis AG Description and Business Overview 6.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Product Portfolio 6.5.5 Novartis AG Recent Developments/Updates 6.6 Pfizer, Inc 6.6.1 Pfizer, Inc Corporation Information 6.6.2 Pfizer, Inc Description and Business Overview 6.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.6.5 Pfizer, Inc Recent Developments/Updates 6.7 Sanofi S.A 6.6.1 Sanofi S.A Corporation Information 6.6.2 Sanofi S.A Description and Business Overview 6.6.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Portfolio 6.7.5 Sanofi S.A Recent Developments/Updates 6.8 UCB Pharma Limited 6.8.1 UCB Pharma Limited Corporation Information 6.8.2 UCB Pharma Limited Description and Business Overview 6.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Portfolio 6.8.5 UCB Pharma Limited Recent Developments/Updates 6.9 Sunovion Pharmaceuticals Limited 6.9.1 Sunovion Pharmaceuticals Limited Corporation Information 6.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview 6.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Portfolio 6.9.5 Sunovion Pharmaceuticals Limited Recent Developments/Updates 6.10 Valeant Pharmaceuticals International, Inc 6.10.1 Valeant Pharmaceuticals International, Inc Corporation Information 6.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview 6.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.10.5 Valeant Pharmaceuticals International, Inc Recent Developments/Updates 6.11 Zogenix 6.11.1 Zogenix Corporation Information 6.11.2 Zogenix Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Zogenix Anti-epileptic Drugs for Pediatrics Product Portfolio 6.11.5 Zogenix Recent Developments/Updates 6.12 GW Pharmaceuticals 6.12.1 GW Pharmaceuticals Corporation Information 6.12.2 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.12.4 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio 6.12.5 GW Pharmaceuticals Recent Developments/Updates 6.13 Insys 6.13.1 Insys Corporation Information 6.13.2 Insys Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.13.4 Insys Anti-epileptic Drugs for Pediatrics Product Portfolio 6.13.5 Insys Recent Developments/Updates 6.14 Zynerba 6.14.1 Zynerba Corporation Information 6.14.2 Zynerba Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Zynerba Anti-epileptic Drugs for Pediatrics Product Portfolio 6.14.5 Zynerba Recent Developments/Updates 7 Anti-epileptic Drugs for Pediatrics Manufacturing Cost Analysis 7.1 Anti-epileptic Drugs for Pediatrics Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics 7.4 Anti-epileptic Drugs for Pediatrics Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Anti-epileptic Drugs for Pediatrics Distributors List 8.3 Anti-epileptic Drugs for Pediatrics Customers 9 Anti-epileptic Drugs for Pediatrics Market Dynamics 9.1 Anti-epileptic Drugs for Pediatrics Industry Trends 9.2 Anti-epileptic Drugs for Pediatrics Growth Drivers 9.3 Anti-epileptic Drugs for Pediatrics Market Challenges 9.4 Anti-epileptic Drugs for Pediatrics Market Restraints 10 Global Market Forecast 10.1 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Type (2022-2027) 10.2 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Application (2022-2027) 10.3 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Anti-epileptic Drugs for Pediatrics by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Anti-epileptic Drugs for Pediatrics by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Anti-epileptic Drugs for Pediatrics Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Anti-epileptic Drugs for Pediatrics Covered in This Study Table 5. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2016-2021) Table 7. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Anti-epileptic Drugs for Pediatrics Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Anti-epileptic Drugs for Pediatrics Manufacturing Sites and Area Served Table 11. Manufacturers Anti-epileptic Drugs for Pediatrics Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Anti-epileptic Drugs for Pediatrics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-epileptic Drugs for Pediatrics as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Anti-epileptic Drugs for Pediatrics Sales by Region (2016-2021) & (K Units) Table 16. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2016-2021) Table 17. Global Anti-epileptic Drugs for Pediatrics Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Anti-epileptic Drugs for Pediatrics Sales by Country (2016-2021) & (K Units) Table 19. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2016-2021) Table 20. North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2016-2021) Table 22. Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2016-2021) & (K Units) Table 23. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2016-2021) Table 24. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2016-2021) Table 30. Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2016-2021) & (K Units) Table 31. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2016-2021) Table 32. Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2016-2021) Table 38. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Type (2016-2021) Table 39. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2016-2021) Table 40. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) by Type (2016-2021) Table 41. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Type (2016-2021) Table 42. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Type (2016-2021) Table 43. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Application (2016-2021) Table 44. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2016-2021) Table 45. Global Anti-epileptic Drugs for Pediatrics Revenue (Million US$) by Application (2016-2021) Table 46. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Application (2016-2021) Table 47. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Application (2016-2021) Table 48. Mylan N.V Corporation Information Table 49. Mylan N.V Description and Business Overview Table 50. Mylan N.V Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Mylan N.V Anti-epileptic Drugs for Pediatrics Product Table 52. Mylan N.V Recent Developments/Updates Table 53. Cephalon, Inc Corporation Information Table 54. Cephalon, Inc Description and Business Overview Table 55. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Table 57. Cephalon, Inc Recent Developments/Updates Table 58. GlaxoSmithKline plc Corporation Information Table 59. GlaxoSmithKline plc Description and Business Overview Table 60. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Table 62. GlaxoSmithKline plc Recent Developments/Updates Table 63. Janssen Pharmaceuticals Corporation Information Table 64. Janssen Pharmaceuticals Description and Business Overview Table 65. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Table 67. Janssen Pharmaceuticals Recent Developments/Updates Table 68. Novartis AG Corporation Information Table 69. Novartis AG Description and Business Overview Table 70. Novartis AG Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Novartis AG Anti-epileptic Drugs for Pediatrics Product Table 72. Novartis AG Recent Developments/Updates Table 73. Pfizer, Inc Corporation Information Table 74. Pfizer, Inc Description and Business Overview Table 75. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Table 77. Pfizer, Inc Recent Developments/Updates Table 78. Sanofi S.A Corporation Information Table 79. Sanofi S.A Description and Business Overview Table 80. Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Table 82. Sanofi S.A Recent Developments/Updates Table 83. UCB Pharma Limited Corporation Information Table 84. UCB Pharma Limited Description and Business Overview Table 85. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Table 87. UCB Pharma Limited Recent Developments/Updates Table 88. Sunovion Pharmaceuticals Limited Corporation Information Table 89. Sunovion Pharmaceuticals Limited Description and Business Overview Table 90. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 91. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Table 92. Sunovion Pharmaceuticals Limited Recent Developments/Updates Table 93. Valeant Pharmaceuticals International, Inc Corporation Information Table 94. Valeant Pharmaceuticals International, Inc Description and Business Overview Table 95. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 96. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Table 97. Valeant Pharmaceuticals International, Inc Recent Developments/Updates Table 98. Zogenix Corporation Information Table 99. Zogenix Description and Business Overview Table 100. Zogenix Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 101. Zogenix Anti-epileptic Drugs for Pediatrics Product Table 102. Zogenix Recent Developments/Updates Table 103. GW Pharmaceuticals Corporation Information Table 104. GW Pharmaceuticals Description and Business Overview Table 105. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 106. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Table 107. GW Pharmaceuticals Recent Developments/Updates Table 108. Insys Corporation Information Table 109. Insys Description and Business Overview Table 110. Insys Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 111. Insys Anti-epileptic Drugs for Pediatrics Product Table 112. Insys Recent Developments/Updates Table 113. Zynerba Corporation Information Table 114. Zynerba Description and Business Overview Table 115. Zynerba Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 116. Zynerba Anti-epileptic Drugs for Pediatrics Product Table 117. Zynerba Recent Developments/Updates Table 118. Production Base and Market Concentration Rate of Raw Material Table 119. Key Suppliers of Raw Materials Table 120. Anti-epileptic Drugs for Pediatrics Distributors List Table 121. Anti-epileptic Drugs for Pediatrics Customers List Table 122. Anti-epileptic Drugs for Pediatrics Market Trends Table 123. Anti-epileptic Drugs for Pediatrics Growth Drivers Table 124. Anti-epileptic Drugs for Pediatrics Market Challenges Table 125. Anti-epileptic Drugs for Pediatrics Market Restraints Table 126. Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2022-2027) & (K Units) Table 127. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Type (2022-2027) Table 128. Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Type (2022-2027) & (US$ Million) Table 129. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share Forecast by Type (2022-2027) Table 130. Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2022-2027) & (K Units) Table 131. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Application (2022-2027) Table 132. Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Application (2022-2027) & (US$ Million) Table 133. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share Forecast by Application (2022-2027) Table 134. Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Region (2022-2027) & (K Units) Table 135. Global Anti-epileptic Drugs for Pediatrics Sales Market Share Forecast by Region (2022-2027) Table 136. Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Region (2022-2027) & (US$ Million) Table 137. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share Forecast by Region (2022-2027) Table 138. Research Programs/Design for This Report Table 139. Key Data Information from Secondary Sources Table 140. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Anti-epileptic Drugs for Pediatrics Figure 2. Global Anti-epileptic Drugs for Pediatrics Market Share by Type in 2020 & 2027 Figure 3. 1st Generation Product Picture Figure 4. 2nd Generation Product Picture Figure 5. 3rd Generation Product Picture Figure 6. Global Anti-epileptic Drugs for Pediatrics Market Share by Application in 2020 & 2027 Figure 7. Hospitals Figure 8. Retail Pharmacies Figure 9. Online Pharmacies Figure 10. Global Anti-epileptic Drugs for Pediatrics Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 11. Global Anti-epileptic Drugs for Pediatrics Market Size 2016-2027 (US$ Million) Figure 12. Global Anti-epileptic Drugs for Pediatrics Sales 2016-2027 (K Units) Figure 13. Global Anti-epileptic Drugs for Pediatrics Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 14. Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturers in 2020 Figure 15. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers in 2020 Figure 16. The Global 5 and 10 Largest Anti-epileptic Drugs for Pediatrics Players: Market Share by Revenue in 2020 Figure 17. Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 18. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2016-2021) Figure 19. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region in 2020 Figure 20. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2016-2021) Figure 21. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region in 2020 Figure 22. U.S. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 23. Canada Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Germany Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. France Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. U.K. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Italy Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Russia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. China Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Japan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. South Korea Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. India Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Australia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Taiwan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Indonesia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Thailand Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Malaysia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Philippines Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Vietnam Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Mexico Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Brazil Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Argentina Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Turkey Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Saudi Arabia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. U.A.E Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Sales Market Share of Anti-epileptic Drugs for Pediatrics by Type (2016-2021) Figure 47. Sales Market Share of Anti-epileptic Drugs for Pediatrics by Application (2016-2021) Figure 48. Sales Market Share of Anti-epileptic Drugs for Pediatrics by Application in 2020 Figure 49. Revenue Share of Anti-epileptic Drugs for Pediatrics by Application (2016-2021) Figure 50. Revenue Share of Anti-epileptic Drugs for Pediatrics by Application in 2020 Figure 51. Manufacturing Cost Structure of Anti-epileptic Drugs for Pediatrics Figure 52. Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics Figure 53. Anti-epileptic Drugs for Pediatrics Industrial Chain Analysis Figure 54. Channels of Distribution Figure 55. Distributors Profiles Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation Figure 58. Key Executives Interviewed

Mylan N.V Cephalon, Inc GlaxoSmithKline plc Janssen Pharmaceuticals Novartis AG Pfizer, Inc Sanofi S.A UCB Pharma Limited Sunovion Pharmaceuticals Limited Valeant Pharmaceuticals International, Inc Zogenix GW Pharmaceuticals Insys Zynerba